The expanding role of GLP 1 receptor agonists: a narrative review of current evidence and future directions eClinicalMedicine Current Insights, Advantages and Challenges of Small Molecule Glucagon like Peptide 1 Receptor Agonists: A Scoping Review Published in Journal of Brown Hospital Medicine Key Findings: Duration Reduction: The study found that GLP 1 therapy significantly shortens the duration of BoNT A effects: In chronic migraine treatment, the mean duration dropped from 14.0 weeks to between 11.8 Most people think GLP 1 drugs explain everything, but your gut runs three separate GLP pathways that control appetite, digestion, and metabolic signaling. The new research shows that each one communicates a different